Disease-specific programs comprise a significant proportion of the research conducted at the Human Microbiology Institute. The founders of the HMI have made amazing studies in advancing our understating of the mechanisms by which the microbiota influences human diseases, including several diseases that were previously not considered to be infectious.
We have discovered principally new mechanisms of microbiota-host interactions, which provide a basis for the next-generation of microbiota research aimed at understanding how diseases, including age-related and neurodegenerative diseases, are developed and established, and at successfully identifying new ways of preventing and managing these disorders.
Investigators at the HMI apply cutting-edge approaches to both improve the efficacy of treatments for known diseases and characterize previously undistinguished types of human diseases.
The results of these studies will further our understanding of the role of the microbiota in many conditions for which effective treatments are not available, including Alzheimer’s disease, Parkinson’s disease, “Jewish diseases”, and dementia, as well as certain infectious diseases, metabolic disorders, cancers, etc. By understanding the root causes and pathogenesis of these diseases, we may be able to identify novel therapeutic targets and thereby design new strategies to treat these diseases.